{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 447554700
| IUPAC_name = (11''R'')-2-methyl-11-[(morpholin-4-yl)methyl]-3-(naphthalene-1-carbonyl)-9-oxa-1-azatricyclo[6.3.1.0⁴,¹²]dodeca-2,4(12),5,7-tetraene
| image = WIN 55,212-2-2D-skeletal.svg
| width = 200px

<!--Clinical data-->
| tradename =  
| legal_CA = Schedule II
| legal_UK = Class B
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 131543-22-1
| PubChem = 5311501
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 4470978
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 73295
| IUPHAR_ligand = 733
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 188
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 5H31GI9502

<!--Chemical data-->
| C=27 | H=26 | N=2 | O=3 
| molecular_weight = 426.52 g/mol
| smiles = CC1=C(C2=C3N1[C@@H](COC3=CC=C2)CN4CCOCC4)C(=O)C5=CC=CC6=CC=CC=C65
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C27H26N2O3/c1-18-25(27(30)22-9-4-7-19-6-2-3-8-21(19)22)23-10-5-11-24-26(23)29(18)20(17-32-24)16-28-12-14-31-15-13-28/h2-11,20H,12-17H2,1H3/t20-/m1/s1
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = HQVHOQAKMCMIIM-HXUWFJFHSA-N
}}

[[File:Pancreatic stellate cell cropped.png|thumb|right|[[Pancreatic stellate cell]]s. The cells in the lower frame are under the action of WIN 55,212-2. They are thought to assume a more "[[G0 phase|quiescent]]" phenotype. From Michalski et al., 2008.<ref name="PSCWIN">{{Cite journal |author= Michalski, C.|editor1-last= Gluud |editor1-first= Christian |title= Cannabinoids Reduce Markers of Inflammation and Fibrosis in Pancreatic Stellate Cells |journal= PLoS ONE |volume= 3 |issue= 2 |pages= e1701 |year= 2008 |pmid= 18301776 |doi= 10.1371/journal.pone.0001701 |pmc= 2253501 |bibcode= 2008PLoSO...3.1701M |display-authors=etal}}
</ref>]]
'''WIN 55,212-2''' is a chemical described as an [[aminoalkylindole]] derivative, which produces effects similar to those of [[cannabinoid]]s such as [[tetrahydrocannabinol]] (THC) but has an entirely different [[chemical structure]].<ref>{{cite journal | last1 = Compton | first1 = DR | display-authors = etal   | year = 1992 | title = Aminoalkylindole Analogs: Cannabimimetic Activity of a Class of Compounds Structurally Distinct from Δ<sup>9</sup>-Tetrahydrocannabinol | url = | journal = Journal of Pharmacology and Experimental Therapeutics | volume = 263 | issue = 3| pages = 1118–1126 }}</ref><ref>{{Cite journal | last1 = Ferraro | first1 = L. | last2 = Tomasini | first2 = M. C. | last3 = Gessa | first3 = G. L. | last4 = Bebe | first4 = B. W. | last5 = Tanganelli | first5 = S. | last6 = Antonelli | first6 = T. | title = The Cannabinoid Receptor Agonist WIN 55,212-2 Regulates Glutamate Transmission in Rat Cerebral Cortex: An in Vivo and in Vitro Study | doi = 10.1093/cercor/11.8.728 | journal = Cerebral Cortex | volume = 11 | issue = 8 | pages = 728–733 | year = 2001 | pmid =  11459762| pmc = }}</ref><ref>{{Cite journal |pmid= 12228183 |year= 2002 |author= Zhang, Q.|title= In vitro metabolism of R(+)-2,3-dihydro-5-methyl-3-(morpholinyl)methylpyrrolo 1,2,3-de1,4-benzoxazinyl-(1-naphthalenyl) methanone mesylate, a cannabinoid receptor agonist |volume= 30 |issue= 10 |pages= 1077–1086 |journal= Drug metabolism and disposition: the biological fate of chemicals |doi= 10.1124/dmd.30.10.1077 |display-authors=etal}}
</ref>

WIN 55,212-2 is a potent cannabinoid [[receptor agonist]]<ref>{{Cite journal 
| last1 = Felder | first1 = C. C. 
| last2 = Joyce | first2 = K. E. 
| last3 = Briley | first3 = E. M. 
| last4 = Mansouri | first4 = J. 
| last5 = MacKie | first5 = K. 
| last6 = Blond | first6 = O. 
| last7 = Lai | first7 = Y. 
| last8 = Ma | first8 = A. L. 
| last9 = Mitchell | first9 = R. L. 
| title = Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors 
| journal = Molecular Pharmacology 
| volume = 48 
| issue = 3 
| pages = 443–450 
| year = 1995 
| pmid = 7565624
}}</ref> that has been found to be a potent analgesic<ref>{{Cite journal | last1 = Meng | first1 = I. D. | last2 = Manning | first2 = B. H. | last3 = Martin | first3 = W. J. | last4 = Fields | first4 = H. L. | title = An analgesia circuit activated by cannabinoids | journal = Nature | volume = 395 | issue = 6700 | pages = 381–383 | year = 1998 | doi = 10.1038/26481 | pmid =  9759727| pmc = }}</ref> in a rat model of neuropathic pain.<ref>{{Cite journal | last1 = Herzberg | first1 = U. | last2 = Eliav | first2 = E. | last3 = Bennett | first3 = G. J. | last4 = Kopin | first4 = I. J. | title = The analgesic effects of R(+)-WIN 55,212–2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain | doi = 10.1016/S0304-3940(96)13308-5 | journal = Neuroscience Letters | volume = 221 | issue = 2–3 | pages = 157–160 | year = 1997 | pmid =  9121688| pmc = }}</ref> It activates [[p42 MAP kinase|p42]] and [[p44 MAP kinase|p44]] [[MAP kinase]] via receptor-mediated signaling.<ref>{{Cite journal 
| last1 = Bouaboula | first1 = M. 
| last2 = Poinot-Chazel | first2 = C. 
| last3 = Bourrié | first3 = B. 
| last4 = Canat | first4 = X. 
| last5 = Calandra | first5 = B. 
| last6 = Rinaldi-Carmona | first6 = M. 
| last7 = Le Fur | first7 = G. 
| last8 = Casellas | first8 = P. 
| title = Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1 
| journal = The Biochemical Journal 
| volume = 312 
| issue = Pt 2 
| pages = 637–641 
| year = 1995 
| pmid = 8526880 
| pmc = 1136308 | doi=10.1042/bj3120637
}}</ref>

At 5 µM WIN 55,212-2 inhibit [[Adenosine Triphosphate|ATP]] production in [[sperm]] in a [[CB1 receptor|CB<sub>1</sub> receptor]]-dependent fashion.<ref>{{Cite journal |last1= Morgan | first1= D. J. |last2= Muller | first2= C. H. |last3= Murataeva | first3= N. A. |last4= Davis | first4= B. J. |last5= MacKie | first5= K. |title= Δ9-Tetrahydrocannabinol (Δ9-THC) attenuates mouse sperm motility and male fecundity |doi= 10.1111/j.1476-5381.2011.01506.x |journal= British Journal of Pharmacology |volume= 165 |issue= 8 |pages= 2575–2583 |year= 2012 |pmid= 21615727 |pmc=3423255 }}
</ref>

WIN 55,212-2, along with [[HU-210]] and [[JWH-133]], may prevent the inflammation caused by [[amyloid beta]] proteins involved in [[Alzheimer's disease]], in addition to preventing cognitive impairment and loss of neuronal [[genetic markers|markers]]. This anti-inflammatory action is induced through agonist action at [[cannabinoid receptor]]s, which prevents [[microglia]]l activation that elicits the inflammation. Additionally, cannabinoids completely abolish neurotoxicity related to [[Microglia#Activated|microglial activation]] in rat models.{{Citation needed|date=December 2010}}

WIN 55,212-2 is a full agonist at the [[CB1 receptor|CB<sub>1</sub> cannabinoid receptor]] ([[Dissociation constant|''K''<sub>i</sub>]]&nbsp;=&nbsp;1.9&nbsp;nM) and has much higher affinity than [[tetrahydrocannabinol|THC]] (''K''<sub>i</sub>&nbsp;=&nbsp;41&nbsp;nM) for this receptor.<ref>{{Cite journal |pmid= 8450470 |year= 1993 |author= Kuster, J. E.|title= Aminoalkylindole binding in rat cerebellum: selective displacement by natural and synthetic cannabinoids |volume= 264 |issue= 3 |pages= 1352–1363 |journal = The Journal of Pharmacology and Experimental Therapeutics |display-authors=etal}}
</ref>

WIN 55,212-2 reduces voluntary wheel running in laboratory mice, but with effects that depend on both genetic background and sex.<ref>{{cite journal  |vauthors=Keeney BK, etal |title=Sex differences in cannabinoid receptor-1 (CB1) pharmacology in mice selectively bred for high voluntary wheel-running behavior |journal=Pharmacology, Biochemistry and Behavior |volume=101 |issue=4 |pages=528–537 |year=2012 |doi=10.1016/j.pbb.2012.02.017}}</ref>

WIN 55,212-2 is illegal in the UK.<ref name="legislation.gov.uk">{{cite web|url=http://www.legislation.gov.uk/uksi/2013/239/article/4/made|title=The Misuse of Drugs Act 1971 (Amendment) Order 2013}}</ref>

==See also==
* [[WIN 48,098]] (Pravadoline)
* [[WIN 54,461]] (6-Bromopravadoline)
* [[WIN 55,225]] (JWH-200)
* [[WIN 56,098]]

== References ==
{{reflist}}

==External links==
* [http://www.enzolifesciences.com/BML-CR105/win-55-212-2/ Enzo Life Sciences] Win 55,212-2 Data Sheet
* The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 ([[TRPV1]]) and evokes peripheral antihyperalgesia via [[calcineurin]]. ''2006 Jul 18; {{PubMed|16849427}}''
* [http://www.jneurosci.org/cgi/content/full/25/8/1904?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&andorexacttitle=and&andorexacttitleabs=and&fulltext=cannabinoid+alzheimer%27s&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT JNeurosci.org] Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation
* [https://www.newscientist.com/article.ns?id=dn10330 New Scientist]: Hope for cannabis-based drug for Alzheimer's

{{Cannabinoids}}
{{Hallucinogens}}
{{Cannabinoid receptor modulators}}
{{Transient receptor potential channel modulators}}

[[Category:Aminoalkylindoles]]
[[Category:Cannabinoids]]
[[Category:Morpholines]]
[[Category:Naphthoylindoles]]
[[Category:WIN compounds]]
[[Category:CB1 receptor agonists]]